top of page

Innovation finds a way.

 

Developing therapeutics that target the TGF-B signaling pathway

MANAGEMENT

barry-hart-1_edited.jpg

CEO

Barry hart, PH.D

Dr. Hart has over 15 years of leadership experience at pharmaceutical and biotechnology companies including Bayer, Scios, ViroBay, Inc. and Medivation. Barry has been responsible for identifying and partnering with CROs to advance pharmaceutical research programs from screening hit to development. After receiving his Ph.D. from University of Michigan, Barry did post-doctoral work at University of California, Berkeley.

bottom of page